A Multinational, Multicenter, Randomized, Open-Label Study to Evaluate the Impact of a 91-Day Extended Cycle Oral Contraceptive Regimen, Compared to Two 28-day Standard Oral Contraceptive Regimens, on Hemostatic Parameters in Healthy Women.

Trial Profile

A Multinational, Multicenter, Randomized, Open-Label Study to Evaluate the Impact of a 91-Day Extended Cycle Oral Contraceptive Regimen, Compared to Two 28-day Standard Oral Contraceptive Regimens, on Hemostatic Parameters in Healthy Women.

Completed
Phase of Trial: Phase II

Latest Information Update: 21 Mar 2015

At a glance

  • Drugs Ethinylestradiol/levonorgestrel (Primary) ; Ethinylestradiol; Ethinylestradiol/desogestrel
  • Indications Pregnancy
  • Focus Biomarker; Pharmacodynamics
  • Most Recent Events

    • 23 Jun 2012 Results presented at the 12th Congress of the European Society of Contraception.
    • 06 Feb 2012 Actual end date Feb 2012 added as reported by ClinicalTrials.gov.
    • 06 Feb 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top